Tolero has a pathway-centric pipeline of new investigational agents aimed at targeting abnormalities in cell function in the context of pathway inhibition. Our approach is to develop specific inhibitors of signaling pathways and identify diseases dependent upon these pathways. This concept is at the center of the personalized medicine philosophy, in which targeted therapeutics can be tailored for individual patients with a defined genetic or molecular subtype of disease.

Tolero pipeline chart showing the various assets in development

Targeted therapy is at the heart of
our pipeline.

Pipeline >

See why we’re investigating MCL-1
as a potential apoptosis inhibitor.

MCL-1 >

Learn about our clinical trials
currently underway.